## Anna K Langenbruch

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4139794/publications.pdf

Version: 2024-02-01

516710 580821 28 693 16 25 citations g-index h-index papers 30 30 30 666 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Nail involvement as a predictor of concomitant psoriatic arthritis in patients with psoriasis. British Journal of Dermatology, 2014, 171, 1123-1128.	1.5	120
2	The German National Program on Psoriasis Health Care 2005–2015: results and experiences. Archives of Dermatological Research, 2016, 308, 389-400.	1.9	47
3	Quality of health care of atopic eczema in Germany: results of the national health care study AtopicHealth. Journal of the European Academy of Dermatology and Venereology, 2014, 28, 719-726.	2.4	45
4	Topology of psoriasis in routine care: results from highâ€resolution analysis of 2009 patients. British Journal of Dermatology, 2019, 181, 358-365.	1.5	42
5	Quality of psoriasis care in Germany: results of the national health care study "PsoHealth3― Archives of Dermatological Research, 2016, 308, 401-408.	1.9	41
6	Nail psoriasis as a severity indicator: results from the PsoReal study. Patient Related Outcome Measures, $2011, 2, 1$ .	1.2	38
7	Characterizing treatmentâ€related patient needs in atopic eczema: insights for personalized goal orientation. Journal of the European Academy of Dermatology and Venereology, 2020, 34, 142-152.	2.4	34
8	Does the Dermatology Life Quality Index (DLQI) underestimate the diseaseâ€specific burden of psoriasis patients?. Journal of the European Academy of Dermatology and Venereology, 2019, 33, 123-127.	2.4	32
9	Costâ€ofâ€illness of psoriasis – results of a German crossâ€sectional study. Journal of the European Academy of Dermatology and Venereology, 2018, 32, 174-180.	2.4	30
10	Quality of Life Measures for Dermatology: Definition, Evaluation, and Interpretation. Current Dermatology Reports, 2012, 1, 148-159.	2.1	27
11	Definition of psoriasis severity in routine clinical care: current guidelines fail to capture the complexity of long-term psoriasis management. British Journal of Dermatology, 2018, 179, 1385-1391.	1.5	25
12	Clinical course, treatment modalities, and quality of life in patients with congenital melanocytic nevi $\hat{a} \in ``data from the German CMN registry. JDDG - Journal of the German Society of Dermatology, 2017, 15, 159-167.$	0.8	24
13	Therapeutic Benefits in Atopic Dermatitis Care from the Patients' Perspective: Results of the German National Health Care Study †Atopic Health'. Dermatology, 2014, 228, 350-359.	2.1	20
14	Time to revise the Dermatology Life Quality Index scoring in psoriasis treatment guidelines. Journal of the European Academy of Dermatology and Venereology, 2019, 33, e267-e269.	2.4	19
15	Costâ€ofâ€illness of atopic dermatitis in Germany: data from dermatology routine care. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 1346-1356.	2.4	19
16	Quality of psoriasis care in Germany – results from the nationwide health care studies PsoHealth 2004â€2017. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 1536-1542.	2.4	18
17	Quality of psoriasis care from the patients' perspective – results of the national health care study PsoReal. European Journal of Dermatology, 2012, 22, 518-524.	0.6	18
18	Sex-related impairment and patient needs/benefits in anogenital psoriasis: Difficult-to-communicate topics and their impact on patient-centred care. PLoS ONE, 2020, 15, e0235091.	2,5	17

#	Article	lF	CITATIONS
19	Quality of life measurement in chronic wounds and inflammatory skin diseases: Definitions, standards and instruments. Wound Medicine, 2014, 5, 29-38.	2.7	16
20	Measurement of healthcare quality in atopic dermatitis $\hat{a}\in$ development and application of a set of quality indicators. Journal of the European Academy of Dermatology and Venereology, 2018, 32, 2237-2243.	2.4	14
21	Disease burden and treatment needs of patients with psoriasis in sexually-sensitive and visible body areas: results from a large-scale survey in routine care. European Journal of Dermatology, 2020, 30, 267-278.	0.6	10
22	Patient benefits in the treatment of psoriasis: longâ€term outcomes in German routine care 2007–2014. Journal of the European Academy of Dermatology and Venereology, 2016, 30, 1829-1833.	2.4	9
23	Disease burden and patient needs and benefits in anogenital psoriasis: developmental specificities for personâ€centred healthcare of emerging adults and adults. Journal of the European Academy of Dermatology and Venereology, 2020, 34, 1010-1018.	2.4	9
24	Determinants of costs and benefits in psoriasis routine care: results from a crossâ€sectional nationwide study in Germany. Journal of the European Academy of Dermatology and Venereology, 2021, 35, e63-e65.	2.4	6
25	Benefits of a membership in a psoriasis patient organisation: a quasi-experimental longitudinal study. Archives of Dermatological Research, 2018, 310, 807-813.	1.9	4
26	Measuring patient-relevant benefits in the treatment of psoriasis with the Patient Benefit Index: development and preliminary validation of a 10-item short form. British Journal of Dermatology, 2022, 187, 588-589.	1.5	3
27	Determinants of costs and benefits in atopic dermatitis routine care in Germany. Journal of the European Academy of Dermatology and Venereology, 2022, 36, 1450-1455.	2.4	3
28	Development and Validation Features of the Patient Benefit Index for the Treatment of Allergic Rhinoconjunctivitis with Allergen Immunotherapy. Journal of Asthma and Allergy, 2022, Volume 15, 611-621.	3.4	0